CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenues:
Premiums earned, net (Net of ceded premiums of $120 and $126 for the three months ended September 30, 2021 and 2020, respectively; net of ceded premiums of $370 and $383 for the nine months ended September 30, 2021 and 2020, respectively)		$ 203,657	$ 167,075	$ 598,390	$ 501,100
Direct Contracting revenue		222,647	0	439,020	0
Other income		859	1,994	2,550	5,555
Total revenues		427,163	169,069	1,039,960	506,655
Operating expenses:
Net medical claims incurred		436,422	144,846	1,109,375	410,540
Salaries and benefits		73,364	16,628	201,555	57,339
General and administrative expenses		45,749	29,847	129,983	79,798
Premium deficiency reserve expense (benefit)		20,761	(772)	48,661	(16,357)
Depreciation and amortization		120	138	398	413
Other expense		0	0	191	0
Total operating expenses		576,416	190,687	1,490,163	531,733
Loss from operations		(149,253)	(21,618)	(450,203)	(25,078)
Change in fair value of warrants payable		(115,152)	20,029	(66,146)	31,903
Interest expense		413	9,268	2,817	25,560
Amortization of notes and securities discounts		13	4,408	13,681	14,935
Gain on derivative		0	(68,081)	0	(87,475)
Net (loss) income		$ (34,527)	$ 12,758	$ (400,555)	$ (10,001)
Per share data:
Net (loss) income per share attributable to common stockholders - basic (in dollars per share)	[1]	$ (0.08)	$ 0.06	$ (0.98)	$ (0.11)
Net (loss) income per share attributable to common stockholders - diluted (in dollars per share)	[1]	$ (0.08)	$ 0.02	$ (0.98)	$ (0.11)
Weighted average number of common shares outstanding
Basic weighted average number of common shares and common shares equivalents outstanding (in shares)	[1]	414,572,706	88,863,244	410,417,493	88,616,116
Diluted weighted average number of common shares and common shares equivalents outstanding (in shares)	[1]	414,572,706	248,133,335	410,417,493	88,616,116
Unrealized (loss) gain on available-for-sale investments		$ (197)	$ (611)	$ (620)	$ 718
Comprehensive (loss) income		$ (34,724)	$ 12,147	$ (401,175)	$ (9,283)

[1] Prior period results have been adjusted to reflect the exchange of Legacy Clover's common stock for Clover Class B Common Stock at an exchange ratio of approximately 2.0681 in January 2021 as a result of the Business Combination. See Note 3 (Business Combination) for additional information. Because the Corporation had a net loss during the three and nine months ended September 30, 2021, and a net loss during the nine months ended September 30, 2020, the Corporation’s potentially dilutive securities, which include stock options, restricted stock, preferred stock and warrants to purchase shares of common stock and preferred stock, have been excluded from the computation of diluted net loss per share, as the effect would be anti-dilutive.